SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
ARIAD Pharmaceuticals
An SI Board Since September 1996
Posts SubjectMarks Bans Symbol
4474 134 0 ARIA
Emcee:  jaybe Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
4174Today's announced 90 layoffs imho reflect the fact ARIA is setting the stagcivic08801-3/29/2016
4173WSJ article highlights previously reported remission in AML with pona/chemo/SCT.jaybe33/28/2016
4172For EGFR Exon 20 its "activity" naive, but afatinib, osimertinib, and jaybe-3/24/2016
4171Just to be clear, "TKI naive" isn't quite accurate - it's naivBiomaven13/24/2016
4170AP32788 Phase 1/2 trial listed on clinicaltrials.gov... 105 patients, 4 cohortsjaybe13/23/2016
4169So much for the bullish cross.testad-3/23/2016
4168Bullish cross in MACD and Stochastic oscillator. On watch for clear above 6.68.hollyhunter-3/23/2016
4167Pona for lung cancer?...UK group finds 1-2% of NSCLC with ABL1 mutations... &qujaybe-3/23/2016
4166Merck et al finds synergy for Wee1 inhibitor + Rida... Since Merck abandoned Ridtktom-3/19/2016
4165tktom-3/19/2016
4164IST for Pona in RET NSCLC lowers dose to 30mg... A few changes to locations, wijaybe-3/18/2016
4163Merck et al finds synergy for Wee1 inhibitor + Rida... In a screen of 22,737 exjaybe-3/17/2016
4162HER2+T790M is 4% of resistant patients - that would be an obvious 2nd-line groupBiomaven-3/17/2016
4161Very interested to see cohorts for P2 portion of initial trial. With this broadjaybe-3/17/2016
4160Very good potency, and a potential EGFR pan-inhibitor: >>AP32788 inhibiteBiomaven33/17/2016
4159AP32788 abstract at AACR suggests broad activity in EGFR and Her2 NSCLC.... 264jaybe-3/16/2016
4158It is increasingly clear that Denner's plan (or lack thereof according to soVidpok1-3/15/2016
4157Upcoming poster presentation on pona in neuroblastoma at ASPHO... ASPHO (The Amjaybe-3/13/2016
4156When briga's PFS curves separate significantly from criz, and they will, thetktom-3/12/2016
4155Keep in mind patients on briga will stay on drug more than twice as long as crizjaybe13/12/2016
4154Crizotinib sales were $488 million in 2015, is that enough revenue to be shared tktom-3/12/2016
4153First IST for briga to start at UNC... Trial will explore briga in 2nd line aftjaybe-3/11/2016
4152The disparity between the IBB and Ariad continues to widen. The IBB is off the Vidpok1-3/10/2016
4151Here is an example of the promiscuous target specificity of PON being helpful bymulanoon2007-3/6/2016
4150Interesting reading the comments on the recent activity. Even the negative posVidpok1-3/4/2016
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News